$TLXTelix Pharmaceuticals Ltd

📅 Upcoming

🕒 Recent(90d)

News

• 3 steps for taking on Novartis in radiopharma: Curium up first
  To successfully challenge Novartis on two planned fronts, Curium will need to overcome the unique challenges posed by radiopharmaceutical supply to get products to patients and win market share.
  biospace · 4d ago
• Novartis secures new radioligand in $900M deal as competition strengthens
  As an imposing new competitor begins to take shape, radiopharma leader Novartis has beefed up its pipeline by licensing a preclinical radioligand therapy from a specialist Chinese biotech.
  fiercebiotech · 11d ago
• Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecasts
  Deals for Chinese radiopharmaceutical assets have been rare to date and there is a limited pool of potential Western buyers available, Sleuth said.
  biospace · 12d ago
• Sleuth forecasts 2027 jump in Western license deals for Chinese radioligand therapies
  Deals for Chinese radiopharmaceutical assets have been rare to date and there is a limited pool of potential Western buyers available, Sleuth said.
  biospace · 12d ago
• Telix and radioisotope maker ITM merge in deal worth up to $2.35B
  Telix Pharmaceuticals is buying German radioisotope manufacturer ITM Isotope Technologies Munich SE for $1.65 billion upfront, but some deal milestones hinge on a recently rejected drug. The merger…
  endpoints · 12d ago
• Telix buys ITM for $1.65B in ‘supercritical’ radiopharma M&A
  Aside from its manufacturing and distribution footprint, ITM Isotope Technologies Munich will give Telix Pharmaceuticals the late-stage ITM-11, being developed for gastroenteropancreatic neuroendoc…
  biospace · 12d ago
• Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition
  Telix has struck a deal to buy ITM Isotope Technologies Munich for $1.65 billion upfront, securing an R&D pipeline led by a rival to Novartis’ Lutathera and a radiopharmaceutical supply network.
  fiercebiotech · 12d ago
• STAT+: Radiopharma companies merge after one receives surprise FDA rejection
  ITM Isotope Technologies Munich SE and Telix Pharmaceuticals, two leading companies in the burgeoning radiopharmaceuticals field, are merging.
  stat · 13d ago
• After rejection, FDA approves Telix’s Pixclara, the first FET-PET imaging drug for brain cancer
  The FDA has signed off on the first-ever glioma drug imaging diagnostic more than a year after it initially rejected the med.
  fiercebiotech · 18d ago
• Beyond China: Five other overseas destinations for biopharma dollars
  As geopolitical tensions between the U.S. and China grow increasingly complicated, here are five alternative territories for biotech investments.
  biospace · 24d ago